Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.10 +0.47%

+$0.11 today

Market cap
$865.32M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.44M

Average 0.33M

AKTS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Aktis Oncology, Inc.NASDAQ: AKTS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 79.8%

Gross margin was 79.8% in Q1 FY2026.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
79.8%-20.2 pp QoQ
Last fiscal yearDec 2025
100.0%+0.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+0.0 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+0.0pp

Gross Margin vs competitors

How AKTS compares with its peers on the latest reported figures

  • AKTS's FY2025 gross margin of 100.0% is the highest of the 5 companies compared; the peer median is 63.7%.
  • Its year-over-year change of +0.0 pp is the 3rd highest of 5, against a peer median of +3.9 pp.
AKTS Competitors Peer median
Gross Margin for AKTS and competitors
Company Period LTM level YoY 3-year change
AKTSAktis Oncology, Inc.FY2025100.0% +0.0 pp—
IMCRImmunocore Holdings plcLTM Mar 202698.8% -0.2 pp+1.6 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
IMNMImmunome, Inc.FY202557.4% -42.6 pp—
BCYCBicycle Therapeutics plcLTM Mar 2026-11.9% +506.2 pp+0.0 pp
AURAAura Biosciences, Inc.FY2025— ——
Peer median (excluding AKTS) 63.7%+3.9 pp+0.0 pp

Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.49M6.5M
Cost of Revenue0000
Gross Profit001.49M6.5M
Gross Margin——100.0%100.0%
Research & Development14.3M25.92M40.95M67.45M
Selling, General & Admin5.11M7.68M11.31M12.6M
Operating Expenses19.76M34.79M53.54M81.18M
Depreciation & Amortization445K1.2M1.58M2.33M
EBITDA(17.48M)(27.45M)(42.41M)(61.4M)
EBITDA Margin——-2851.7%-945.1%
Operating Income(19.76M)(34.79M)(52.05M)(74.68M)
Operating Margin——-3500.3%-1149.5%
Interest Income1.65M5.38M8.1M11.01M
Interest Expense0000
Other Income / Expenses1.84M6.15M8.07M10.95M
Income Before Tax(17.93M)(28.64M)(43.98M)(63.73M)
Pre-Tax Margin——-2957.6%-980.9%
Income Tax Expense0000
Net Income(17.93M)(28.64M)(43.98M)(63.73M)
Net Margin——-2957.6%-980.9%
EPS (Basic)(0.51)(0.82)(1.26)(1.19)
EPS (Diluted)(0.51)(0.82)(1.26)(1.19)
Weighted Avg Shares34.86M34.86M34.86M52.52M
Weighted Avg Shares (Diluted)34.86M34.86M34.86M52.52M

Aktis Oncology, Inc.

NASDAQ:AKTS

Intrinsic Alpha fair value

Locked

Current Price

$16.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.